The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-01 and is reviewed periodically as new material appears.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
=== One-Pot Synthesis === One-pot reactions involve combining all reactants simultaneously under appropriate conditions. This straightforward approach has proven successful for many simpler cage structures, particularly those formed through imine condensation. The success of one-pot synthesis often depends on the reversible nature of bond formation, allowing the system to self-correct and converge on the thermodynamically favored product. The reaction conditions, such as temperature, solvent choice, and concentration, play crucial roles in determining the outcome. For example, in imine cage synthesis, polar aprotic solvents like dichloromethane or chloroform are often preferred as they facilitate imine formation while allowing the removal of water byproduct. Additionally, techniques such as slow addition of components or temperature control can be employed to enhance selectivity towards the desired cage product.
Severe diabetic hypoglycemia Diabetic ketoacidosis advanced enough to result in unconsciousness from a combination of severe hyperglycemia, dehydration and shock, and exhaustion Hyperosmolar nonketotic coma in which extreme hyperglycemia and dehydration alone are sufficient to cause unconsciousness.
He has faced a total of "25 arrests, 35 detoxes, and more than 200 hospital visits." A planned Australian and New Zealand Pentagram tour scheduled for August 2025 was cancelled upon local feminist groups learning about Liebling's conviction.
== Examples of variants == Over 1,000 known mutations can lead to thalassaemia or hemoglobin variants. A research database of hemoglobin variants is maintained by Penn State University. A few of these variants are listed below.
=== Angiogenesis === The formation of new blood vessels is essential for tumor survival and expansion. Intracrines like VEGF and angiogenin regulate angiogenesis within tumor cells and surrounding endothelial cells. Inhibiting intracrine trafficking of angiogenin to the nucleus has been shown to blunt cancer cell proliferation, making this an emerging therapeutic target.
Sources: en.wikipedia.org
Beans, lima beans, yucca, yams, arracacia, caigua, pumpkin, and squash were available depending on the region. Wild vegetables eaten included cochayuyo, watercress, and cattail. Fruits consumed included lucuma, pacay, guava, and cucumbers. Meat came from either domesticated animals such as llamas, alpacas, and guinea pigs, or wild animals such as guanacos, vicuñas, deer, viscacha, partridges, doves, and ducks. Fish was also available. These foods would have been cooked and served in various ways. While on campaign, Incan armies made frequent use of dehydrated foods that could be prepared, preserved, and transported in sufficient quantities. During marches through desert regions, soldiers relied on a combination of dehydrated foods and fresh meat from the llamas accompanying the army as a means of transport.
== Workflow == Cells containing the protein complement desired are grown. Proteins are then extracted from the mixture and digested with a protease to produce a peptide mixture. The peptide mixture is then loaded directly onto a microcapillary column and the peptides are separated by hydrophobicity and charge. As the peptides elute from the column, they are ionized and separated by m/z in the first stage of tandem mass spectrometry. The selected ions undergo collision-induced dissociation or other process to induce fragmentation. The charged fragments are separated in the second stage of tandem mass spectrometry. The "fingerprint" of each peptide's fragmentation mass spectrum is used to identify the protein from which they derive by searching against a sequence database with commercially available software (e.g. Sequest or Mascot). Examples of sequence databases are the Genpept database or the PIR database. After the database search, each peptide-spectrum match (PSM) needs to be evaluated for validity. This analysis allows researchers to profile various biological systems.
The International Standard for the Prohibited List is the standard published by the World Anti-Doping Agency (WADA) that lists substances prohibited in competitive sport. It is updated at least once per year as required by the World Anti-Doping Code. The adoption of the first World Anti-Doping Code (the Code) occurred at the 2nd World Conference on Doping in Sport in March 2003 in Copenhagen, Denmark. It was there that WADA assumed the responsibility of maintaining, updating, and publishing the List of Prohibited Substances and Methods (the List) in sport. The List is to be updated and published by WADA at least annually. WADA specifies that the List generally includes any substance that meets any two of the following criteria: it enhances sport performance, it represents a health risk to the athlete, it violates the spirit of sport (as defined in the WADA Code). Substances and techniques that are prohibited by WADA fall into the following categories: S0 non-approved substances; S1 anabolic agents; S2 peptide hormones, growth factors, related substances, and mimetics; S3 beta-2 agonists; S4 hormone and metabolic modulators; S5 diuretics and masking agents; prohibited methods (M1 blood doping, M2 manipulation of samples, M3 gene doping); S6 stimulants; S7 narcotics; S8 cannabinoids; S9 glucocorticoids; P1 beta-blockers.
WOSM's emblem and trademark is a purple circular logo with a white fleur-de-lis in the centre with a purple five-point star in each outer lobe, surrounded by a circle of white rope tied with a reef or square knot at the base.
Fe + CuSO4 → FeSO4 + Cu In high school and general chemistry education, copper sulfate is used as an electrolyte for galvanic cells, usually as a cathode solution. For example, in a zinc/copper cell, copper ion in copper sulfate solution absorbs electron from zinc and forms metallic copper.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.